Thrombosis Update最新文献_第3页

Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Protocol for a European Delphi study 开发一种决策支持工具，用于在接受临终关怀的患者中继续或减少抗血栓治疗的处方：欧洲德尔菲研究的方案

Q4 Medicine

Thrombosis Update

Pub Date : 2025-05-06 DOI: 10.1016/j.tru.2025.100209

Imene Deneche , Camille Couffignal , Nassima Si Mohammed , Anette Arbjerg Højen , Carme Font , Stavros Konstantinides , Marieke Kruip , Luigi Maiorana , Sebastian Szmit , Denise Abbel , Laurent Bertoletti , Susanne Cannegieter , Adrian Edwards , Michelle Edwards , Alessandra Gava , Jacobijn Gussekloo , Miriam J. Johnson , Rashmi Kumar , Johan Langendoen , Kate Lifford , Isabelle Mahé

Introduction

To develop a European shared decision support tool (SDST), a Delphi process will be used to reach consensus about aspects relating to the continuation or deprescribing of antithrombotic therapy (ATT) in cancer patients at the end of life. As part of the SERENITY project, this study corresponds to work package (WP) 4.

Methods

Findings from SERENITY WPs 1–3 (realist review, flash mob research, epidemiological and qualitative studies) informed the Delphi study. The WP4 steering committee had two objectives. (1) to build a representative expert panel comprising physicians, pharmacists, nurses and psychologists from eight European countries; and (2) to advise on the content of the Delphi form, divided into four sections: context, content, SDST design and trial outcomes. The form was reviewed by the SERENITY patient and public involvement group to ensure that it met patients’ needs. The Delphi study will take place in three rounds held at 6-week intervals, involving experts from eight countries. Consensus will be reached on items with at least 70 % agreement. The steering committee will review and validate the results across the different rounds.

Results

Through this Delphi study, the following aspects will be defined: characterisation of candidate patients for discussion about ATT deprescribing; healthcare team roles in ATT decision-making; specific information and communication requirements for patients when making deprescribing decisions; SDST content priorities; and optimal outcomes for the planned clinical trial.

Conclusion

This study will feed directly into the development and evaluation of the SDST, aimed at reducing complications and improving quality-of-life in end-of-life cancer patients receiving ATT.

为了开发欧洲共享决策支持工具（SDST），将使用德尔福过程就癌症患者生命末期抗血栓治疗（ATT）的继续或处方达成共识。作为SERENITY项目的一部分，本研究符合工作包（WP） 4。方法SERENITY WPs 1-3（现实主义综述、快闪族研究、流行病学和定性研究）的研究结果为Delphi研究提供了依据。WP4指导委员会有两个目标。(1)建立一个由来自欧洲8个国家的医生、药剂师、护士和心理学家组成的具有代表性的专家小组；(2)对德尔菲表的内容提出建议，分为语境、内容、SDST设计和试验结果四个部分。该表格由SERENITY患者和公众参与小组审查，以确保它满足患者的需求。德尔菲研究将分三轮进行，每隔6周进行一次，涉及来自8个国家的专家。在70%以上的共识项上达成共识。指导委员会将审查和验证不同回合的结果。结果通过德尔菲研究，将定义以下方面：讨论ATT处方的候选患者的特征；医疗团队在ATT决策中的作用；患者在作出处方决定时的具体信息和沟通要求；SDST内容优先级；以及计划临床试验的最佳结果。结论本研究将直接为SDST的开发和评估提供依据，旨在减少接受ATT治疗的晚期癌症患者的并发症和提高生活质量。

{"title":"Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Protocol for a European Delphi study","authors":"Imene Deneche , Camille Couffignal , Nassima Si Mohammed , Anette Arbjerg Højen , Carme Font , Stavros Konstantinides , Marieke Kruip , Luigi Maiorana , Sebastian Szmit , Denise Abbel , Laurent Bertoletti , Susanne Cannegieter , Adrian Edwards , Michelle Edwards , Alessandra Gava , Jacobijn Gussekloo , Miriam J. Johnson , Rashmi Kumar , Johan Langendoen , Kate Lifford , Isabelle Mahé","doi":"10.1016/j.tru.2025.100209","DOIUrl":"10.1016/j.tru.2025.100209","url":null,"abstract":"<div><h3>Introduction</h3><div>To develop a European shared decision support tool (SDST), a Delphi process will be used to reach consensus about aspects relating to the continuation or deprescribing of antithrombotic therapy (ATT) in cancer patients at the end of life. As part of the SERENITY project, this study corresponds to work package (WP) 4.</div></div><div><h3>Methods</h3><div>Findings from SERENITY WPs 1–3 (realist review, flash mob research, epidemiological and qualitative studies) informed the Delphi study. The WP4 steering committee had two objectives. (1) to build a representative expert panel comprising physicians, pharmacists, nurses and psychologists from eight European countries; and (2) to advise on the content of the Delphi form, divided into four sections: context, content, SDST design and trial outcomes. The form was reviewed by the SERENITY patient and public involvement group to ensure that it met patients’ needs. The Delphi study will take place in three rounds held at 6-week intervals, involving experts from eight countries. Consensus will be reached on items with at least 70 % agreement. The steering committee will review and validate the results across the different rounds.</div></div><div><h3>Results</h3><div>Through this Delphi study, the following aspects will be defined: characterisation of candidate patients for discussion about ATT deprescribing; healthcare team roles in ATT decision-making; specific information and communication requirements for patients when making deprescribing decisions; SDST content priorities; and optimal outcomes for the planned clinical trial.</div></div><div><h3>Conclusion</h3><div>This study will feed directly into the development and evaluation of the SDST, aimed at reducing complications and improving quality-of-life in end-of-life cancer patients receiving ATT.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100209"},"PeriodicalIF":0.0,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of oral aspirin in prevention of embolic events in infective endocarditis: A systematic review and meta analysis 口服阿司匹林预防感染性心内膜炎栓塞事件的疗效：一项系统综述和meta分析

Q4 Medicine

Thrombosis Update

Pub Date : 2025-05-03 DOI: 10.1016/j.tru.2025.100208

Jonathan Victor Salazar-Ore , Angie Carolina Alonso-Ramírez , Gabriela Vanessa Flores-Monar , Emily Patricia Solarte-Zabaleta , Miguel Ángel Castaneda-Diaz , Ada Lizandra Motino-Villanueva , Anuj Manish-Kakkad , Camila Sanchez-Cruz , Ernesto Calderón-Martínez

Introduction

Infective endocarditis (IE) involves inflammation of the heart's inner lining and valves, leading to complications like embolic events. The role of aspirin in preventing these events is controversial, with concerns about bleeding risk, limiting its use. This meta-analysis evaluates the effectiveness of oral aspirin in preventing embolic events and its adverse outcomes in IE patients.

Methods

A systematic search was conducted on July 20, 2024, across PubMed/MEDLINE, Cochrane, Scopus, Web of Science, EMBASE, and CINAHL for studies comparing aspirin to placebo or no treatment. The protocol was registered in PROSPERO (CRD42024573274).

Results

Five studies involving 1174 participants were included, with three eligible for meta-analysis due to data limitations. Findings on embolic event incidence were inconsistent: one randomized clinical trial (RCT) excluding prior aspirin therapy (OR 1.62, [0.68–3.86], p = 0.29) and a reanalysis examining long-term use (OR 0.80, [0.36–1.78], p = 0.582) found no significant reduction, while another study reported a possible reduction (OR 0.65, [0.43–0.98], p = 0.04). Bleeding rates trended higher in aspirin groups across two studies, though not statistically significant. Mortality data also varied; one study found higher mortality in aspirin users, while another associated chronic antiplatelet therapy with lower mortality, particularly with early initiation after admission.

Conclusion

Aspirin may reduce embolic events in IE, but evidence remains inconclusive due to mixed findings. Aspirin showed a non-significant increase in bleeding risk and mortality, so routine use for embolic prevention in IE is not recommended, highlighting the need for further research to clarify its potential role.

感染性心内膜炎（IE）涉及心脏内膜和瓣膜的炎症，可导致栓塞事件等并发症。阿司匹林在预防这些事件中的作用是有争议的，由于担心出血风险，限制了它的使用。本荟萃分析评估了口服阿司匹林在预防IE患者栓塞事件及其不良后果方面的有效性。方法于2024年7月20日在PubMed/MEDLINE、Cochrane、Scopus、Web of Science、EMBASE和CINAHL上进行系统检索，比较阿司匹林与安慰剂或不治疗的研究。该协议已在PROSPERO （CRD42024573274）中注册。结果纳入5项研究，涉及1174名受试者，其中3项由于数据限制符合meta分析。栓塞事件发生率的研究结果不一致：一项不包括既往阿司匹林治疗的随机临床试验（RCT）（OR 1.62, [0.68-3.86], p = 0.29）和一项检查长期使用阿司匹林的再分析（OR 0.80, [0.36-1.78], p = 0.582）未发现显著降低，而另一项研究报告可能降低（OR 0.65, [0.43-0.98], p = 0.04）。在两项研究中，阿司匹林组的出血率呈上升趋势，尽管没有统计学意义。死亡率数据也各不相同；一项研究发现阿司匹林使用者死亡率较高，而另一项研究发现慢性抗血小板治疗死亡率较低，特别是入院后早期开始治疗。结论：阿司匹林可能减少IE患者的栓塞事件，但由于研究结果不一，证据仍不确定。阿司匹林显示出血风险和死亡率无显著增加，因此不建议常规使用阿司匹林预防IE栓塞，强调需要进一步研究以阐明其潜在作用。

{"title":"Efficacy of oral aspirin in prevention of embolic events in infective endocarditis: A systematic review and meta analysis","authors":"Jonathan Victor Salazar-Ore , Angie Carolina Alonso-Ramírez , Gabriela Vanessa Flores-Monar , Emily Patricia Solarte-Zabaleta , Miguel Ángel Castaneda-Diaz , Ada Lizandra Motino-Villanueva , Anuj Manish-Kakkad , Camila Sanchez-Cruz , Ernesto Calderón-Martínez","doi":"10.1016/j.tru.2025.100208","DOIUrl":"10.1016/j.tru.2025.100208","url":null,"abstract":"<div><h3>Introduction</h3><div>Infective endocarditis (IE) involves inflammation of the heart's inner lining and valves, leading to complications like embolic events. The role of aspirin in preventing these events is controversial, with concerns about bleeding risk, limiting its use. This meta-analysis evaluates the effectiveness of oral aspirin in preventing embolic events and its adverse outcomes in IE patients.</div></div><div><h3>Methods</h3><div>A systematic search was conducted on July 20, 2024, across PubMed/MEDLINE, Cochrane, Scopus, Web of Science, EMBASE, and CINAHL for studies comparing aspirin to placebo or no treatment. The protocol was registered in PROSPERO (CRD42024573274).</div></div><div><h3>Results</h3><div>Five studies involving 1174 participants were included, with three eligible for meta-analysis due to data limitations. Findings on embolic event incidence were inconsistent: one randomized clinical trial (RCT) excluding prior aspirin therapy (OR 1.62, [0.68–3.86], p = 0.29) and a reanalysis examining long-term use (OR 0.80, [0.36–1.78], p = 0.582) found no significant reduction, while another study reported a possible reduction (OR 0.65, [0.43–0.98], p = 0.04). Bleeding rates trended higher in aspirin groups across two studies, though not statistically significant. Mortality data also varied; one study found higher mortality in aspirin users, while another associated chronic antiplatelet therapy with lower mortality, particularly with early initiation after admission.</div></div><div><h3>Conclusion</h3><div>Aspirin may reduce embolic events in IE, but evidence remains inconclusive due to mixed findings. Aspirin showed a non-significant increase in bleeding risk and mortality, so routine use for embolic prevention in IE is not recommended, highlighting the need for further research to clarify its potential role.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100208"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144088817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

National and regional incidence patterns of venous thromboembolism in Finland during 1998–2021 with corresponding mortality trends in 1998–2019 1998-2021年芬兰静脉血栓栓塞的国家和地区发病率模式以及1998-2019年相应的死亡率趋势

Q4 Medicine

Thrombosis Update

Pub Date : 2025-04-08 DOI: 10.1016/j.tru.2025.100207

Lasse Myllylahti , Jari Haukka , Eero Hirvensalo , Riitta Lassila

Objectives

Previous research suggest that venous thromboembolism (VTE) -related mortality have been declining over the recent decades, despite the increasing trend of pulmonary embolism (PE) incidence. There is evidence of some regional differences in VTE incidence. We wanted to evaluate the national and regional 21st century VTE incidence in Finland, as well as respective national VTE mortality trends.

Patients and methods

In this nationwide registry study, anonymous participants were patients with VTE diagnoses (I26 or I80) during hospital visits or VTE-related documentation of primary cause of death. To assess incidence, we recorded VTE-related hospital visits from the HILMO registry of the Finnish Institute for Health and Welfare. To assess mortality, we recorded deaths with a VTE diagnosis as a primary cause of death from the registries of Statistics Finland. Additionally, we acquired the data about pulmonary CT angiographies from STUK, which is the radiation and nuclear safety authority in Finland.

Results

At the national level, the PE incidence doubled during the study period, while the incidence rates of deep vein thrombosis remained stable. Some regional variances in VTE incidence were encountered. The usage of radiological examinations to diagnose PE have become more frequent during the study period. The mortality for VTE peaked in 2004, following the clear declining trend during the follow-up period.

Conclusion

Despite the remarkable increase in PE incidence, the mortality rates have been constantly declining from 2004. These results are valuable for the future epidemiological research of VTE.

目的先前的研究表明，近几十年来，尽管肺栓塞（PE）的发病率呈上升趋势，但静脉血栓栓塞（VTE）相关的死亡率一直在下降。有证据表明静脉血栓栓塞的发病率存在一些地区差异。我们想评估21世纪芬兰国家和地区静脉血栓栓塞发病率，以及各自国家静脉血栓栓塞死亡率趋势。患者和方法在这项全国性的登记研究中，匿名参与者是在医院就诊期间被诊断为静脉血栓栓塞（I26或I80）或有静脉血栓栓塞相关主要死因记录的患者。为了评估发病率，我们记录了芬兰健康与福利研究所HILMO登记处与vte相关的医院就诊情况。为了评估死亡率，我们从芬兰统计局登记处记录了静脉血栓栓塞诊断为主要死因的死亡病例。此外，我们从芬兰的辐射和核安全权威机构STUK获得了肺部CT血管造影的数据。结果在全国范围内，PE发病率在研究期间翻了一番，而深静脉血栓的发病率保持稳定。静脉血栓栓塞的发生率存在一些区域差异。在研究期间，影像学检查诊断PE的频率越来越高。静脉血栓栓塞的死亡率在2004年达到顶峰，在随访期间呈明显下降趋势。结论自2004年以来，尽管PE发病率显著上升，但死亡率却在不断下降。这些结果对今后静脉血栓栓塞的流行病学研究具有一定的参考价值。

{"title":"National and regional incidence patterns of venous thromboembolism in Finland during 1998–2021 with corresponding mortality trends in 1998–2019","authors":"Lasse Myllylahti , Jari Haukka , Eero Hirvensalo , Riitta Lassila","doi":"10.1016/j.tru.2025.100207","DOIUrl":"10.1016/j.tru.2025.100207","url":null,"abstract":"<div><h3>Objectives</h3><div>Previous research suggest that venous thromboembolism (VTE) -related mortality have been declining over the recent decades, despite the increasing trend of pulmonary embolism (PE) incidence. There is evidence of some regional differences in VTE incidence. We wanted to evaluate the national and regional 21st century VTE incidence in Finland, as well as respective national VTE mortality trends.</div></div><div><h3>Patients and methods</h3><div>In this nationwide registry study, anonymous participants were patients with VTE diagnoses (I26 or I80) during hospital visits or VTE-related documentation of primary cause of death. To assess incidence, we recorded VTE-related hospital visits from the HILMO registry of the Finnish Institute for Health and Welfare. To assess mortality, we recorded deaths with a VTE diagnosis as a primary cause of death from the registries of Statistics Finland. Additionally, we acquired the data about pulmonary CT angiographies from STUK, which is the radiation and nuclear safety authority in Finland.</div></div><div><h3>Results</h3><div>At the national level, the PE incidence doubled during the study period, while the incidence rates of deep vein thrombosis remained stable. Some regional variances in VTE incidence were encountered. The usage of radiological examinations to diagnose PE have become more frequent during the study period. The mortality for VTE peaked in 2004, following the clear declining trend during the follow-up period.</div></div><div><h3>Conclusion</h3><div>Despite the remarkable increase in PE incidence, the mortality rates have been constantly declining from 2004. These results are valuable for the future epidemiological research of VTE.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100207"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound assisted, catheter-directed thrombolysis for acute intermediate-high risk pulmonary embolism: Focus on safety for oncological patients 超声辅助导管溶栓治疗急性中高危肺栓塞：重点关注肿瘤患者的安全性

Q4 Medicine

Thrombosis Update

Pub Date : 2025-03-22 DOI: 10.1016/j.tru.2025.100206

Claudia Colombo , Lorenzo Tua , Nicolò Capsoni , Francesco Musca , Ilaria Emanuela Bossi , Filippo Russo , Mario Iannaccone , Andrea Discalzi , Luciana D'Angelo , Fabrizio Oliva , Marco Solcia , Alice Sacco

引用次数: 0

Novel method for pulmonary embolism prognosis: Right to left ventricular volume ratio (RLVR) on pulmonary angiography (CTPA) 肺栓塞预后的新方法：肺动脉造影（CTPA）右左心室容积比（RLVR）

Q4 Medicine

Thrombosis Update

Pub Date : 2025-03-05 DOI: 10.1016/j.tru.2025.100203

Aykut Yucal, Mustafa Burak Sayhan

Introduction

Right ventricular dysfunction is the main cause of mortality in patients with acute massive pulmonary embolism (PE) and early diagnosis is extremely important. This study aimed to investigate whether the right/left ventricular volume ratio (RLVR) calculated using pulmonary angiography (CTPA) is a valuable tool for PE prognosis.

Method

Clinical, echocardiographic and pulmonary angiography data of cases diagnosed with pulmonary embolism in the emergency department between January 2021 and December 2023 were retrospectively evaluated. Patients were stratified according to the presence of massive PE, one month mortality and pulmonary embolism severity index (PESI) score. Clinical, laboratory and radiographic parameters were compared to search for prognostic factors.

Results

Of the 210 patients, the mean age was 67 ± 15 years, 46 % were male, and 42 % had massive PE. The right/left ventricular volume ratio was significantly higher in patients with massive PE, in those who died within one month after admission; and in patients with PESI Class III. When the cut-off value of right/left ventricular volume ratio was accepted as >1.7, its predictive value for acute PE mortality was higher than other CTPA and echocardioraphy measurements (AUC = 0.706).

Conclusion

An increased right/left ventricular volume ratio on CTPA, a valuable tool for diagnosing right ventricular dysfunction, is associated with a worse prognosis in subjects with pulmonary thromboembolism.

摘要右室功能障碍是急性大面积肺栓塞（PE）患者死亡的主要原因，早期诊断至关重要。本研究旨在探讨肺动脉造影（CTPA）计算的右/左心室容积比（RLVR）是否为PE预后的有价值的工具。方法回顾性分析2021年1月至2023年12月急诊诊断为肺栓塞病例的临床、超声心动图和肺动脉造影资料。根据是否存在大量肺栓塞、1个月死亡率和肺栓塞严重程度指数（PESI）评分对患者进行分层。临床，实验室和影像学参数进行比较，以寻找预后因素。结果210例患者平均年龄为67±15岁，男性占46%，有大量PE的占42%。在入院后1个月内死亡的大量PE患者中，右/左心室容积比明显更高；以及PESI III类患者。当接受右/左心室容积比临界值为>；1.7时，其对急性PE死亡率的预测价值高于其他CTPA和超声心动图测量值（AUC = 0.706）。结论CTPA右/左心室容积比升高与肺血栓栓塞患者预后不良相关，CTPA是诊断右室功能障碍的重要工具。

{"title":"Novel method for pulmonary embolism prognosis: Right to left ventricular volume ratio (RLVR) on pulmonary angiography (CTPA)","authors":"Aykut Yucal, Mustafa Burak Sayhan","doi":"10.1016/j.tru.2025.100203","DOIUrl":"10.1016/j.tru.2025.100203","url":null,"abstract":"<div><h3>Introduction</h3><div>Right ventricular dysfunction is the main cause of mortality in patients with acute massive pulmonary embolism (PE) and early diagnosis is extremely important. This study aimed to investigate whether the right/left ventricular volume ratio (RLVR) calculated using pulmonary angiography (CTPA) is a valuable tool for PE prognosis.</div></div><div><h3>Method</h3><div>Clinical, echocardiographic and pulmonary angiography data of cases diagnosed with pulmonary embolism in the emergency department between January 2021 and December 2023 were retrospectively evaluated. Patients were stratified according to the presence of massive PE, one month mortality and pulmonary embolism severity index (PESI) score. Clinical, laboratory and radiographic parameters were compared to search for prognostic factors.</div></div><div><h3>Results</h3><div>Of the 210 patients, the mean age was 67 ± 15 years, 46 % were male, and 42 % had massive PE. The right/left ventricular volume ratio was significantly higher in patients with massive PE, in those who died within one month after admission; and in patients with PESI Class III. When the cut-off value of right/left ventricular volume ratio was accepted as >1.7, its predictive value for acute PE mortality was higher than other CTPA and echocardioraphy measurements (AUC = 0.706).</div></div><div><h3>Conclusion</h3><div>An increased right/left ventricular volume ratio on CTPA, a valuable tool for diagnosing right ventricular dysfunction, is associated with a worse prognosis in subjects with pulmonary thromboembolism.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100203"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimorbidity and VTE 多发病和静脉血栓栓塞

Q4 Medicine

Thrombosis Update

Pub Date : 2025-03-01 DOI: 10.1016/j.tru.2025.100204

Lucy A. Norris (Editors in Chief), Emmanouil S. Papadakis (Editors in Chief)

引用次数: 0

Thank you reviewers 谢谢审稿人

Q4 Medicine

Thrombosis Update

Pub Date : 2025-03-01 DOI: 10.1016/j.tru.2025.100205

引用次数: 0

Discordance and bleeding in critically ill patients with COVID-19 receiving unfractionated heparin: A comparison between aPTT and anti-factor Xa activity level monitoring aPTT与抗Xa因子活性水平监测在重症COVID-19患者未分离肝素治疗中的差异及出血

Q4 Medicine

Thrombosis Update

Pub Date : 2025-02-27 DOI: 10.1016/j.tru.2025.100202

Merijn C. Reuland , Thijs F. van Haaps , Pieter O.L.P. Broeren , Nick van Es , Claire E. Dijkslag-van der Laan , Alexander P.J. Vlaar , Michiel Coppens , Marcella C.A. Müller

Introduction

COVID-19 is associated with hypercoagulability and an increased risk of thrombotic complications. In critically ill COVID-19 patients with thrombosis receiving unfractionated heparin (UFH), heparin resistance is frequently observed when the activated Partial Thromboplastin Time (aPTT) is used for monitoring. It is unclear whether UFH monitoring with anti-factor Xa (anti-Xa) is beneficial.

Methods

Retrospective cohort of critically ill COVID-19 patients treated with UFH in a single center tertiary Intensive Care Unit (ICU) before and after changing treatment protocol from a nurse-driven aPTT guided to an anti-Xa guided UFH dosing protocol. Measurements of aPTT and anti-Xa were simultaneously collected to evaluate discordance. Next, bleeding events while treated using the different treatments protocols was assessed, using the validated HEME scoring system.

Results

We included 149 patients with a median age of 63 years (interquartile range: 59, 70). Among the 715 samples with simultaneous measurements of aPTT and anti-Xa, discordance was observed in 57 % of samples. This was based on a low aPTT and normal anti-Xa activity in 40 %, and a normal aPTT and high anti-Xa activity in 9 %. In the aPTT period 43 of 83 patients developed any bleeding (52 %) compared to 23 of 68 patients (34 %) in the anti-Xa-guided period. In the 83 patients in the aPTT guided group, there were 43 bleeding events in 19 patients, compared to 23 bleeding events in 16 patients in the group guided by anti-Xa activity.

Conclusion

In critically ill patients with COVID-19 receiving UFH, measurement of aPTT and anti-Xa activity are frequently discordant. Anti-Xa monitoring could potentially help in reducing the risk of bleeding.

covid -19与高凝性和血栓性并发症风险增加相关。在接受未分离肝素（UFH）治疗的COVID-19血栓形成危重患者中，当使用活化的部分凝血活素时间（aPTT）进行监测时，经常观察到肝素耐药。目前尚不清楚用抗Xa因子（anti-Xa）监测UFH是否有益。方法回顾性分析单中心三级重症监护室（ICU）重症COVID-19危重患者在从护士驱动的aPTT引导到抗xa引导的UFH给药方案改变前后的治疗方案。同时收集aPTT和抗xa的测量值以评估不一致性。接下来，使用经过验证的HEME评分系统评估使用不同治疗方案治疗时的出血事件。结果纳入149例患者，中位年龄为63岁（四分位数范围：59,70）。在715个同时测定aPTT和anti-Xa的样品中，57%的样品存在不一致。这是基于40%的低aPTT和正常的抗xa活性，9%的aPTT正常和高抗xa活性。在aPTT治疗期间，83例患者中有43例（52%）出现出血，而在抗xa引导治疗期间，68例患者中有23例（34%）出现出血。在aPTT引导组的83例患者中，19例患者发生43例出血事件，而抗xa活性引导组的16例患者发生23例出血事件。结论新冠肺炎危重患者接受UFH治疗时，aPTT和抗xa活性测定经常不一致。抗xa监测可能有助于降低出血的风险。

{"title":"Discordance and bleeding in critically ill patients with COVID-19 receiving unfractionated heparin: A comparison between aPTT and anti-factor Xa activity level monitoring","authors":"Merijn C. Reuland , Thijs F. van Haaps , Pieter O.L.P. Broeren , Nick van Es , Claire E. Dijkslag-van der Laan , Alexander P.J. Vlaar , Michiel Coppens , Marcella C.A. Müller","doi":"10.1016/j.tru.2025.100202","DOIUrl":"10.1016/j.tru.2025.100202","url":null,"abstract":"<div><h3>Introduction</h3><div>COVID-19 is associated with hypercoagulability and an increased risk of thrombotic complications. In critically ill COVID-19 patients with thrombosis receiving unfractionated heparin (UFH), heparin resistance is frequently observed when the activated Partial Thromboplastin Time (aPTT) is used for monitoring. It is unclear whether UFH monitoring with anti-factor Xa (anti-Xa) is beneficial.</div></div><div><h3>Methods</h3><div>Retrospective cohort of critically ill COVID-19 patients treated with UFH in a single center tertiary Intensive Care Unit (ICU) before and after changing treatment protocol from a nurse-driven aPTT guided to an anti-Xa guided UFH dosing protocol. Measurements of aPTT and anti-Xa were simultaneously collected to evaluate discordance. Next, bleeding events while treated using the different treatments protocols was assessed, using the validated HEME scoring system.</div></div><div><h3>Results</h3><div>We included 149 patients with a median age of 63 years (interquartile range: 59, 70). Among the 715 samples with simultaneous measurements of aPTT and anti-Xa, discordance was observed in 57 % of samples. This was based on a low aPTT and normal anti-Xa activity in 40 %, and a normal aPTT and high anti-Xa activity in 9 %. In the aPTT period 43 of 83 patients developed any bleeding (52 %) compared to 23 of 68 patients (34 %) in the anti-Xa-guided period. In the 83 patients in the aPTT guided group, there were 43 bleeding events in 19 patients, compared to 23 bleeding events in 16 patients in the group guided by anti-Xa activity.</div></div><div><h3>Conclusion</h3><div>In critically ill patients with COVID-19 receiving UFH, measurement of aPTT and anti-Xa activity are frequently discordant. Anti-Xa monitoring could potentially help in reducing the risk of bleeding.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"19 ","pages":"Article 100202"},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Direct oral anticoagulants in patients with severe inherited thrombophilia: Real-world data from a tertiary care center 直接口服抗凝剂治疗严重遗传性血栓患者：来自三级保健中心的真实世界数据

Q4 Medicine

Thrombosis Update

Pub Date : 2025-01-31 DOI: 10.1016/j.tru.2025.100201

Omri Cohen , Merav Arnon , Irit Birger , Ophira Salomon , Shadan Lalezari , Orly Efros , Tami Barazani Brutman , Gili Kenet , Aaron Lubetsky , Sarina Levy-Mendelovich

Background

Inherited thrombophilia (IT) predisposes individuals to venous thromboembolism (VTE) and increases the risk for first event VTE as well as for recurrent VTE. Outcomes in patients with IT treated with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs), remain mostly underexplored.

Methods

This retrospective study analyzed VTE patients with severe IT treated with DOACs at a large tertiary center. The MDClone platform was used for data extraction. Main outcomes were rates of VTE recurrence and major bleeding while on treatment with either DOAC or VKAs.

Results

A total of 160 patients with IT were included. The median age was 44.3 and 56.9 % were female. Unprovoked VTE was the most common presentation, accounting for 45.0 % of cases, followed by events provoked by estrogen exposure (21.9 %) and other minor triggers (16.9 %). DOACs were exclusively administered in 82 patients (51.2 %), whereas 78 (48.7 %) received vitamin Kantagonists (VKAs), of whom 40 were later switched to DOACs.

Over a median of 5.2 years follow-up, VTE recurrence was observed in 12.5 %, and associated with higher Charlson comorbidity scores. Patients with unprovoked VTE exhibited the highest recurrence rates (20.8 %). In multivariate analysis recurrence rates were unaffected by gender, age at initial VTE event, comorbidity, thrombophilia subtype, or anticoagulant type. Incidence of major bleeding was low and was also similar across anticoagulant groups.

Conclusion

DOACs and VKAs provide comparable outcomes in patients with IT in terms of VTE recurrence and bleeding risk.

背景：遗传性血栓性疾病（IT）使个体易患静脉血栓栓塞症（VTE），并增加首次发生VTE和复发性VTE的风险。直接口服抗凝剂（DOACs）或维生素K拮抗剂（VKAs）治疗的IT患者的预后仍未得到充分研究。方法回顾性分析在大型三级医疗中心接受DOACs治疗的重症静脉血栓栓塞患者。使用MDClone平台进行数据提取。主要结果是静脉血栓栓塞的复发率和在DOAC或vka治疗期间的大出血。结果共纳入160例IT患者。中位年龄为44.3岁，56.9%为女性。无因性静脉血栓栓塞是最常见的表现，占45.0%的病例，其次是雌激素暴露（21.9%）和其他轻微诱因（16.9%）。82例患者（51.2%）接受doac治疗，78例患者（48.7%）接受维生素Kantagonists （vka）治疗，其中40例患者后来改用doac。在中位5.2年的随访中，静脉血栓栓塞的复发率为12.5%，并伴有较高的Charlson合并症评分。非诱发性静脉血栓栓塞患者复发率最高（20.8%）。在多变量分析中，复发率不受性别、初始静脉血栓栓塞事件的年龄、合并症、血栓形成亚型或抗凝类型的影响。大出血的发生率较低，抗凝治疗组的大出血发生率相似。结论在静脉血栓栓塞复发和出血风险方面，doacs和vka在IT患者中提供了相当的结果。

{"title":"Direct oral anticoagulants in patients with severe inherited thrombophilia: Real-world data from a tertiary care center","authors":"Omri Cohen , Merav Arnon , Irit Birger , Ophira Salomon , Shadan Lalezari , Orly Efros , Tami Barazani Brutman , Gili Kenet , Aaron Lubetsky , Sarina Levy-Mendelovich","doi":"10.1016/j.tru.2025.100201","DOIUrl":"10.1016/j.tru.2025.100201","url":null,"abstract":"<div><h3>Background</h3><div>Inherited thrombophilia (IT) predisposes individuals to venous thromboembolism (VTE) and increases the risk for first event VTE as well as for recurrent VTE. Outcomes in patients with IT treated with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs), remain mostly underexplored.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed VTE patients with severe IT treated with DOACs at a large tertiary center. The MDClone platform was used for data extraction. Main outcomes were rates of VTE recurrence and major bleeding while on treatment with either DOAC or VKAs.</div></div><div><h3>Results</h3><div>A total of 160 patients with IT were included. The median age was 44.3 and 56.9 % were female. Unprovoked VTE was the most common presentation, accounting for 45.0 % of cases, followed by events provoked by estrogen exposure (21.9 %) and other minor triggers (16.9 %). DOACs were exclusively administered in 82 patients (51.2 %), whereas 78 (48.7 %) received vitamin Kantagonists (VKAs), of whom 40 were later switched to DOACs.</div><div>Over a median of 5.2 years follow-up, VTE recurrence was observed in 12.5 %, and associated with higher Charlson comorbidity scores. Patients with unprovoked VTE exhibited the highest recurrence rates (20.8 %). In multivariate analysis recurrence rates were unaffected by gender, age at initial VTE event, comorbidity, thrombophilia subtype, or anticoagulant type. Incidence of major bleeding was low and was also similar across anticoagulant groups.</div></div><div><h3>Conclusion</h3><div>DOACs and VKAs provide comparable outcomes in patients with IT in terms of VTE recurrence and bleeding risk.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"18 ","pages":"Article 100201"},"PeriodicalIF":0.0,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of Rosuvastatin on a murine model of deep vein thrombosis 瑞舒伐他汀对小鼠深静脉血栓形成模型的影响

Q4 Medicine

Thrombosis Update

Pub Date : 2025-01-15 DOI: 10.1016/j.tru.2025.100200

Megan E. Barney , Shenghao Zhou , Anh Le-Cook , Naly Setthavongsack , Gabriel Nager , Jennifer M. Loftis , Randy L. Woltjer , Monica Hinds , Khanh P. Nguyen

Introduction

Rosuvastatin reduces C-reactive protein and cardiovascular mortality. After deep vein thrombosis (DVT), elevated inflammatory markers persist. We hypothesize that statins may reduce the inflammation that may be associated with the development of post thrombotic syndrome (PTS).

Materials and methods

Wildtype CD1 mice were fed either regular chow or 1 mg/kg rosuvastatin diets for 1 week prior to surgically induced DVT. Thrombus weights, plasma inflammatory markers, and histology were examined on postoperative days 3 and 7.

Results

Thrombus weights were equivalent in the rosuvastatin treated mice compared to control mice on day 3 (1.25 mg/g±0.61 vs 1.46 mg/g±0.61, p = 0.23) and day 7 (1.07 mg/g ± 0.39 vs 1.04 mg/g±0.32, p = 0.43). On day 3, rosuvastatin treated mice demonstrated decreased levels of monocyte chemoattractant protein-1(MCP-1) (8.20 pg/mL ± 4.07 vs 17.37 pg/mL ±3.26, p = 0.04) and tumor necrosis factor-α (TNF-α) (2.42 pg/mL ±0.42 vs 4.74 pg/mL ± 0.91, p = 0.02) in comparison to the control mice. On day 7, rosuvastatin treated mice demonstrated increased levels of interferon-γ (IFN-γ) (4.22 pg/mL ±5.02 vs 0.49 pg/mL ±0.01, p = 0.04) in comparison to the control mice. There was a significant increase in collagen deposition seen both in the thrombus (2.00 ± 0.63 vs 0.75 ± 0.46, p = 0.002) and vein wall (2.33 ± 0.82 vs 1.13 ± 0.35 p = 0.008) on day 7 in the rosuvastatin treated animals compared to the control animals.

Conclusions

After DVT, rosuvastatin did not accelerate thrombus resolution nor did it affect thrombus formation. However, rosuvastatin decreases MCP-1 and TNF-α during thrombus formation and increases IFN-γ in early thrombus resolution. Additionally, rosuvastatin may promote positive remodeling within the thrombus but increases vein wall fibrosis.

瑞舒伐他汀降低c反应蛋白和心血管死亡率。深静脉血栓形成（DVT）后，炎症标志物持续升高。我们假设他汀类药物可能会减少与血栓后综合征（PTS）发展相关的炎症。材料和方法野生型CD1小鼠在手术诱发DVT前1周分别饲喂常规饲料或瑞舒伐他汀饲料1 mg/kg。术后第3天和第7天检测血栓重量、血浆炎症标志物和组织学。结果瑞舒伐他汀治疗后第3天（1.25 mg/g±0.61 vs 1.46 mg/g±0.61,p = 0.23）和第7天（1.07 mg/g±0.39 vs 1.04 mg/g±0.32,p = 0.43）小鼠血栓重量与对照组相当。第3天，瑞舒伐他汀治疗小鼠单核细胞化学引诱蛋白-1（MCP-1）水平（8.20 pg/mL±4.07 vs 17.37 pg/mL±3.26,p = 0.04）和肿瘤坏死因子-α (TNF-α)水平（2.42 pg/mL±0.42 vs 4.74 pg/mL±0.91,p = 0.02）较对照组小鼠降低。第7天，瑞舒伐他汀治疗小鼠的干扰素-γ (IFN-γ)水平较对照组小鼠升高（4.22 pg/mL±5.02 vs 0.49 pg/mL±0.01,p = 0.04）。与对照组相比，瑞舒伐他汀治疗的动物在第7天的血栓（2.00±0.63 vs 0.75±0.46,p = 0.002）和静脉壁（2.33±0.82 vs 1.13±0.35 p = 0.008）中胶原沉积均显著增加。结论瑞舒伐他汀不加速血栓溶解，也不影响血栓形成。然而，瑞舒伐他汀在血栓形成过程中降低MCP-1和TNF-α，在血栓溶解早期增加IFN-γ。此外，瑞舒伐他汀可能促进血栓内的正性重构，但增加静脉壁纤维化。

{"title":"The Effect of Rosuvastatin on a murine model of deep vein thrombosis","authors":"Megan E. Barney , Shenghao Zhou , Anh Le-Cook , Naly Setthavongsack , Gabriel Nager , Jennifer M. Loftis , Randy L. Woltjer , Monica Hinds , Khanh P. Nguyen","doi":"10.1016/j.tru.2025.100200","DOIUrl":"10.1016/j.tru.2025.100200","url":null,"abstract":"<div><h3>Introduction</h3><div>Rosuvastatin reduces C-reactive protein and cardiovascular mortality. After deep vein thrombosis (DVT), elevated inflammatory markers persist. We hypothesize that statins may reduce the inflammation that may be associated with the development of post thrombotic syndrome (PTS).</div></div><div><h3>Materials and methods</h3><div>Wildtype CD1 mice were fed either regular chow or 1 mg/kg rosuvastatin diets for 1 week prior to surgically induced DVT. Thrombus weights, plasma inflammatory markers, and histology were examined on postoperative days 3 and 7.</div></div><div><h3>Results</h3><div>Thrombus weights were equivalent in the rosuvastatin treated mice compared to control mice on day 3 (1.25 mg/g±0.61 vs 1.46 mg/g±0.61, <em>p</em> = 0.23) and day 7 (1.07 mg/g ± 0.39 vs 1.04 mg/g±0.32, <em>p</em> = 0.43). On day 3, rosuvastatin treated mice demonstrated decreased levels of monocyte chemoattractant protein-1(MCP-1) (8.20 pg/mL ± 4.07 vs 17.37 pg/mL ±3.26, <em>p</em> = 0.04) and tumor necrosis factor-α (TNF-α) (2.42 pg/mL ±0.42 vs 4.74 pg/mL ± 0.91, <em>p</em> = 0.02) in comparison to the control mice. On day 7, rosuvastatin treated mice demonstrated increased levels of interferon-γ (IFN-γ) (4.22 pg/mL ±5.02 vs 0.49 pg/mL ±0.01, <em>p</em> = 0.04) in comparison to the control mice. There was a significant increase in collagen deposition seen both in the thrombus (2.00 ± 0.63 vs 0.75 ± 0.46, <em>p</em> = 0.002) and vein wall (2.33 ± 0.82 vs 1.13 ± 0.35 <em>p</em> = 0.008) on day 7 in the rosuvastatin treated animals compared to the control animals.</div></div><div><h3>Conclusions</h3><div>After DVT, rosuvastatin did not accelerate thrombus resolution nor did it affect thrombus formation. However, rosuvastatin decreases MCP-1 and TNF-α during thrombus formation and increases IFN-γ in early thrombus resolution. Additionally, rosuvastatin may promote positive remodeling within the thrombus but increases vein wall fibrosis.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"18 ","pages":"Article 100200"},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0